Literature DB >> 16100525

Neutrophils and the kallikrein-kinin system in proteinase-activated receptor 4-mediated inflammation in rodents.

Steeve Houle1, Martin D Papez, Mara Ferazzini, Morley D Hollenberg, Nathalie Vergnolle.   

Abstract

1 We evaluated a potential role for proteinase-activated receptor 4 (PAR(4)) in a rodent paw inflammation model, with a focus on two main features of inflammation: (1) oedema and (2) granulocyte recruitment. 2 A PAR(4) antagonist (Pepducin P4pal-10; palmitoyl-SGRRYGHALR-NH(2)) reduced both the oedema and granulocyte recruitment induced by a localized administration of carrageenan in the rat hind paw, pointing to a key role for PAR(4) in this inflammation model. 3 Further, intraplantar injection in the mouse hind paw of a PAR(4) agonist (AYPGKF-NH(2)), but not its standard PAR(4)-inactive peptide control (YAPGKF-NH(2)), caused an inflammatory reaction characterized by oedema (increased paw thickness) and granulocyte recruitment (increased paw myeloperoxidase activity). The PAR(4) agonist-induced effects were inhibited in mice pretreated with pepducin P4pal10. 4 These PAR(4) agonist-mediated effects were not affected by pretreatment with inhibitors of either NO production or prostaglandin release (L-NAME and indomethacin, respectively). 5 However, selective immuno-depletion of neutrophils significantly reduced PAR(4) agonist-induced oedema formation. 6 Moreover, AYPGKF-NH(2)-induced oedema was also reduced by pretreatment with either a kinin B(2) receptor antagonist (icatibant) or a tissue or plasma kallikrein inhibitor (FE999024 and FE999026, respectively), but not with a kinin B(1) receptor antagonist (SSR240612). 7 We conclude: (1) that PAR(4) plays an important role in the inflammatory response as it mediates some of the hallmarks of inflammation and (2) that PAR(4)-mediated oedema is dependent on the recruitment of neutrophils and components of the kallikrein-kinin system.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16100525      PMCID: PMC1751199          DOI: 10.1038/sj.bjp.0706371

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  46 in total

1.  Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism.

Authors:  M Steinhoff; N Vergnolle; S H Young; M Tognetto; S Amadesi; H S Ennes; M Trevisani; M D Hollenberg; J L Wallace; G H Caughey; S E Mitchell; L M Williams; P Geppetti; E A Mayer; N W Bunnett
Journal:  Nat Med       Date:  2000-02       Impact factor: 53.440

Review 2.  International Union of Pharmacology. XXVIII. Proteinase-activated receptors.

Authors:  Morley D Hollenberg; Steven J Compton
Journal:  Pharmacol Rev       Date:  2002-06       Impact factor: 25.468

3.  Activation of protease-activated receptor (PAR)-1, PAR-2, and PAR-4 stimulates IL-6, IL-8, and prostaglandin E2 release from human respiratory epithelial cells.

Authors:  Nithiananthan Asokananthan; Peter T Graham; Joshua Fink; Darryl A Knight; Anthony J Bakker; Andrew S McWilliam; Philip J Thompson; Geoffrey A Stewart
Journal:  J Immunol       Date:  2002-04-01       Impact factor: 5.422

4.  Involvement of tissue kallikrein but not plasma kallikrein in the development of symptoms mediated by endogenous kinins in acute pancreatitis in rats.

Authors:  Thomas Griesbacher; Irmgard Rainer; Beate Tiran; D Michael Evans
Journal:  Br J Pharmacol       Date:  2002-11       Impact factor: 8.739

5.  Determination of bradykinin B2 receptor in vivo phosphorylation sites and their role in receptor function.

Authors:  A Blaukat; A Pizard; A Breit; C Wernstedt; F Alhenc-Gelas; W Muller-Esterl; I Dikic
Journal:  J Biol Chem       Date:  2001-08-21       Impact factor: 5.157

6.  Proteinase-activated receptor-1 agonists attenuate nociception in response to noxious stimuli.

Authors:  Samuel Asfaha; Valentine Brussee; Kevin Chapman; Douglas W Zochodne; Nathalie Vergnolle
Journal:  Br J Pharmacol       Date:  2002-03       Impact factor: 8.739

7.  Essential role for neutrophil recruitment to the liver in concanavalin A-induced hepatitis.

Authors:  Claudine S Bonder; Maureen N Ajuebor; Lori D Zbytnuik; Paul Kubes; Mark G Swain
Journal:  J Immunol       Date:  2004-01-01       Impact factor: 5.422

8.  Protease-activated receptors 1 and 4 mediate thrombin signaling in endothelial cells.

Authors:  Hiroshi Kataoka; Justin R Hamilton; David D McKemy; Eric Camerer; Yao-Wu Zheng; Abby Cheng; Courtney Griffin; Shaun R Coughlin
Journal:  Blood       Date:  2003-07-17       Impact factor: 22.113

9.  Characterization of thrombin-induced leukocyte rolling and adherence: a potential proinflammatory role for proteinase-activated receptor-4.

Authors:  Nathalie Vergnolle; Claudia K Derian; Michael R D'Andrea; Martin Steinhoff; Patricia Andrade-Gordon
Journal:  J Immunol       Date:  2002-08-01       Impact factor: 5.422

10.  Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation.

Authors:  Lidija Covic; Meghna Misra; Jehangir Badar; Christopher Singh; Athan Kuliopulos
Journal:  Nat Med       Date:  2002-09-23       Impact factor: 53.440

View more
  31 in total

1.  Serine protease inhibition reduces post-ischemic granulocyte recruitment in mouse intestine.

Authors:  Thomas Gobbetti; Nicolas Cenac; Jean-Paul Motta; Corinne Rolland; Laurence Martin; Patricia Andrade-Gordon; Martin Steinhoff; Elisabetta Barocelli; Nathalie Vergnolle
Journal:  Am J Pathol       Date:  2011-11-07       Impact factor: 4.307

Review 2.  New insights into protease-activated receptor 4 signaling pathways in the pathogenesis of inflammation and neuropathic pain: a literature review.

Authors:  Yanju Bao; Yebo Gao; Liping Yang; Xiangying Kong; Honggang Zheng; Wei Hou; Baojin Hua
Journal:  Channels (Austin)       Date:  2015       Impact factor: 2.581

Review 3.  Turning receptors on and off with intracellular pepducins: new insights into G-protein-coupled receptor drug development.

Authors:  Katie O'Callaghan; Athan Kuliopulos; Lidija Covic
Journal:  J Biol Chem       Date:  2012-02-28       Impact factor: 5.157

Review 4.  Protease-activated receptor 4: a critical participator in inflammatory response.

Authors:  Qiang Fu; Jing Cheng; Yebo Gao; Yonglei Zhang; Xiaobing Chen; Jianguo Xie
Journal:  Inflammation       Date:  2015-04       Impact factor: 4.092

Review 5.  Pharmacology, biodistribution, and efficacy of GPCR-based pepducins in disease models.

Authors:  Sarah L Tressel; Georgios Koukos; Boris Tchernychev; Suzanne L Jacques; Lidija Covic; Athan Kuliopulos
Journal:  Methods Mol Biol       Date:  2011

6.  Increased expression of protease-activated receptor 2 and 4 within dorsal root ganglia in a rat model of bone cancer pain.

Authors:  Yanju Bao; Wei Hou; Liping Yang; Rui Liu; Yebo Gao; Xiangying Kong; Zhan Shi; Weidong Li; Honggang Zheng; Shulong Jiang; Baojin Hua
Journal:  J Mol Neurosci       Date:  2014-10-26       Impact factor: 3.444

Review 7.  Proteinases, proteinase-activated receptors (PARs) and the pathophysiology of cancer and diseases of the cardiovascular, musculoskeletal, nervous and gastrointestinal systems.

Authors:  Kristina K Hansen; Katerina Oikonomopoulou; Yang Li; Morley D Hollenberg
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-10-19       Impact factor: 3.000

8.  Protease activated receptors 1 and 4 sensitize TRPV1 in nociceptive neurones.

Authors:  Vittorio Vellani; Anna M Kinsey; Massimiliano Prandini; Sabine C Hechtfischer; Peter Reeh; Pier C Magherini; Chiara Giacomoni; Peter A McNaughton
Journal:  Mol Pain       Date:  2010-09-27       Impact factor: 3.395

9.  Tissue kallikrein elicits cardioprotection by direct kinin b2 receptor activation independent of kinin formation.

Authors:  Julie Chao; Hang Yin; Lin Gao; Makoto Hagiwara; Bo Shen; Zhi-Rong Yang; Lee Chao
Journal:  Hypertension       Date:  2008-09-02       Impact factor: 10.190

10.  Interleukin-1β increased the expression of protease-activated receptor 4 mRNA and protein in dorsal root ganglion neurons.

Authors:  Zhaojin Wang; Dan Chen; Rui Zhang; Shuhong An; Zaifeng Zhang; Qingyuan Ma
Journal:  Neurochem Res       Date:  2013-06-18       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.